je.st
news
Tag: pediatric
Merck Announces Collaboration with the Medicines Patent Pool to Expand Access to Pediatric Formulations of Raltegravir in Developing Countries
2015-02-24 09:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced an agreement with the Medicines Patent Pool (MPP) to license its pediatric formulations of raltegravir for use in treating HIV-1 infection in infants and children from four weeks to under 12 years of age in developing countries. This is the MPPs first agreement to provide access to an HIV integrase inhibitor for use in combination HIV therapy for infants and children in this age range. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Ian McConnell, 908-740-1921orInvestors:Joe Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: access
countries
expand
pool
Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients
2015-02-09 15:30:43| Biotech - Topix.net
Oncolytics Biotech Inc. today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration for REOLYSIN for the treatment of high grade gliomas in pediatric patients. Oncolytics has conducted three previous clinical studies in brain cancers including gliomas, and has found that REOLYSIN can infect a variety of brain tumors when delivered intravenously.
Tags: high
drug
grade
patients
EOS imaging Announces Installation in Switzerlanda s Largest Pediatric Hospital
2014-11-25 03:15:23| Toys - Topix.net
The installation at UCHZ is the Company's fifth installation in the country. As Switzerland's largest university hospital for children, UCHZ employs 2,000 medical professionals who contribute to the welfare of more than 100,000 young patients each year.
Tags: largest
hospital
installation
imaging
US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteurs Investigational Pediatric Hexavalent Vaccine
2014-10-20 14:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. & SWIFTWATER, Pa. Phase III clinical study data presented at IDWeek in Philadelphia WHITEHOUSE STATION, N.J. & SWIFTWATER, Pa.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN and NYSE:SNY), announced today that the Biologics License Application (BLA) filed for the companies investigational pediatric hexavalent vaccine, DTaP5-IPV-Hib-HepB1, has been accepted for review by the U.S. Food and Drug Administration (FDA). Language: English Contact: MerckMedia:Deb Wambold, (215) 652-2913orInvestors:Justin Holko, (908) 423-5088orSanofi PasteurMedia:Susan Watkins, (570) 957-2563susan.watkins@sanofipasteur.comorInvestors:George Grofik, (908) 981-5560IR@sanofi.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: SAN Exchange: BOURSE Ticker: SNY Exchange: NYSE read more
Tags: review
application
license
accepts
Pediatric Clinical Trials: Special Considerations and Requirements
2014-07-31 01:19:20| drugdiscoveryonline Home Page
Date: Monday, September 8, 2014 Time: 1pm - 2:30pm EDT Duration: 90 Minutes - Online Price: $299 - Introductory Rate
Tags: special
requirements
clinical
considerations